RT Journal Article
SR Electronic
A1 Lederman, Lynne
T1 Maintenance Therapy with ERL and BEV Prolongs Survival in Unresectable mCRC
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 36
SP 10
OP 11
DO 10.1177/155989771436005
UL http://mdc.sagepub.com/content/14/36/10.abstract
AB Cross-talk between vascular endothelial growth factor (VEGF) and the epidermal growth factor receptor (EGFR) are involved in tumor growth and survival; inhibition of either may increase survival in patients with metastatic colorectal cancer (mCRC). However, combining monoclonal antibodies (mAb) targeting VEGF or EGFR in mCRC has not been effective. This article reports on the final results of the Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery study [DREAM; NCT00265824].